Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evotec SEEVOTF 59 Cash Ratio is 1.10 as of Mar. 2026, which is 23% below its 10-year median of 1.43. GuruFocus rates EVOTF with a GF Score™ of 59/100 and a GF Value™ of $13.56. The stock has 5 warning signs investors should review. Among 975 Drug Manufacturers companies, Evotec SE ranks better than 65.03% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Evotec SE Cash Ratio Related Terms
Evotec SE Cash Ratio Historical Data
* Premium members only.
The historical data trend for Evotec SE's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Evotec SE's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVOTF) has a Cash Ratio of 1.10 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Evotec SE and its competitors. This is 23% below median its historical median of 1.43. Over the past decade, Evotec SE's Cash Ratio has ranged from 0.38 to 4.19. According to the industry distribution chart, Evotec SE ranks #341 out of 975 companies in the Drug Manufacturers industry, placing it in the top 35%.
Is Evotec SE's Cash Ratio too high?
Evotec SE's current Cash Ratio of 1.10 is 23% below median its 10-year median of 1.43. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 4.19. The Drug Manufacturers industry median Cash Ratio is 0.60. Evotec SE's value of 1.10 is 83.3% above this industry median. Based on the distribution chart, Evotec SE ranks #341 out of 975 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Evotec SE has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #341 out of 975 companies for Cash Ratio. This puts Evotec SE in the upper half of its industry. The industry median Cash Ratio is 0.60. Evotec SE's value of 1.10 is 83.3% above this benchmark. Historically, Evotec SE's own Cash Ratio has ranged from 0.38 to 4.19 over the past decade. While the company's 10-year median is 1.43 vs. the industry median of 0.60, Evotec SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current Cash Ratio of 1.10 is 83.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Cash Ratio is 1.10, which is 23% below median its own 10-year median of 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (EVOTF) has a current Cash Ratio of 1.10. The stock's GF Value™ is $13.56, compared to a current price of $6.69 — trading 50.7% below its estimated fair value. The current Cash Ratio is 1.10, which is 23% below median its 10-year median of 1.43 and 83.3% above the Drug Manufacturers industry median of 0.60. Evotec SE's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Evotec SE (EVOTF), the current Cash Ratio is 1.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVOTF) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $6.69 is trading 50.7% below its estimated GF Value™ of $13.56.
Key valuation signals for EVOTF:
Cash Ratio: 1.10 (23% below median its 10-year median of 1.43)
GF Value™: $13.56 vs. price of $6.69 (50.7% below fair value)
Industry Position: 83.3% above the Drug Manufacturers median (#341 of 975)
No single metric tells the full story. See the EVOTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
59GF Score
Get the complete analysis for EVOTF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVOTF has been successfully added to your 
